Think about it. Why wouldn't every single branded pharmaceutical company be using this tactic to sidestep generic competition? Maybe because they know it is illegal and they would be punished for doing so. Unless this company is just flying under the FTC's radar, there's no reason why they should not have been brought to task for their practices. I'd also like HHS to investigate if any co-pay coupons are making it into the Part D system. When you have a single supplier pharmacy (i.e. PME), there should be extra scrutiny put on that supplier.
When will the FTC find PME illegal?
Aucun commentaire:
Enregistrer un commentaire